Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB
J Clin Oncol. 2005 23 (1): 133-41

PMID: 15625368 · DOI:10.1200/JCO.2005.03.206

MeSH Terms (16)

Adult Aged Antineoplastic Agents Carcinoma, Renal Cell Female Humans Injections, Subcutaneous Interferon-alpha Interferon alpha-2 Interleukin-2 Kidney Neoplasms Male Middle Aged Neoplasm Metastasis Recombinant Proteins Survival Rate

Connections (1)

This publication is referenced by other Labnodes entities: